NGS has emerged as a promising approach to detect measurable residual disease (MRD) in AML. In this blog we provide an overview of conventional methods currently employed such as Flow Cytometry, and discuss why NGS is a valuable addition to the technologies used for MRD assessment.
Read and download the ArticleDiscover how next-generation sequencing is reshaping CLL prognosis, streamlining the process and offering more comprehensive insights than ever before.
Read and download the ArticleThis study demonstrates the SureSeq™ Myeloid Fusion Complete NGS Workflow Solution V2’s 100% concordance with qPCR and FISH for detecting known chromosomal rearrangements in acute myeloid leukaemia (AML). In addition, the NGS-based approach provides a more comprehensive transcriptomic landscape of fusions in myeloid leukaemias.
Read and download the Scientific posterThis study evaluated the suitability of the SureSeq™ Myeloid MRD Complete NGS Workflow Solution V2 for detection of low-level variants in measurable residual disease (MRD) monitoring. The results show that this NGS approach can reliably detect AML-related genetic variants for SNVs, indels and FLT3-ITDs as low as 0.05% VAF, enabling stronger characterisation of the AML status of research samples.
Read and download the Scientific posterGain an understanding of the relationship between sequencing depth and Variant Allele Frequency (VAF) sensitivity, which plays a significant role in accurately detecting genetic variants, especially in Measurable Residual Disease (MRD) detection.
Read and download the ArticleThis study highlights the ability of the SureSeq™ Myeloid Fusion Panel to detect multiple fusions, identify breakpoints, and capture MECOM overexpression, so your lab can achieve higher efficiency sample classification with a single assay.
Read and download the Application noteWatch OGT expert Alex Hobb’s presentation from ACGS 2024 that highlights how your lab can achieve more accurate sample classification with the SureSeq™ Myeloid Fusion Panel.
Read and download the OGT presentationWe explore the guidelines and the different methods for fusion event detection, including the potential of RNA-based NGS to help pave the way for personalised therapies and improved patient outcomes.
Read and download the ArticleFirst presented at the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, this scientific poster demonstrates the capabilities of our SureSeq™ CLL + CNV V3 Panel in detecting copy number alterations and gene variants in Chronic Lymphocytic Leukaemia (CLL).
Read and download the Scientific posterProf. Dr. med. Klaus. H. Metzeler, MD describes the current technology landscape and prognostic relevance of minimal residual disease (MRD) detection and demonstrates his experience using NGS-based MRD detection in AML, including OGT’s NGS-based SureSeq™ Myeloid MRD Panel.
Read and download the Customer presentationPresented at the 14th Annual Meeting of the Cancer Genomics Consortium, this poster demonstrates our measurable residual disease (MRD) next generation sequencing (NGS) capabilities in acute myeloid leukaemia (AML) monitoring.
Read and download the Scientific posterMyeloid malignancies are a group of diseases with wide heterogeneity. In this blog, we will explore the KMT2A gene, previously known as the MLL gene, and its influence upon myeloid malignancies.
Read and download the Article{{literatureDetailsPage.Summary}}
Read and download the {{literatureDetailsPage.FriendlyResorceType}}
Visit USA site
Visit Canada site
